

1 *Supplementary data*

2

3

4 **Enhancer profiling identifies epigenetic markers of endocrine**
5 **resistance and reveals therapeutic options for metastatic**
6 **castration-resistant prostate cancer patients**

7

8

9 The supplementary file includes 1 supplement with additional clinical methods.

10

11

12 Tesa M. Severson^{1,2,3,*}, Yanyun Zhu^{1,2,*}, Stefan Prekovic^{1,2,*}, Karianne Schuurman¹, Holly M. Nguyen⁴, Lisha G.
13 Brown⁴, Sini Hakkola⁵, Yongsoo Kim^{1,6}, Jeroen Kneppers^{1,2}, Simon Linder^{1,2}, Suzan Stelloo^{1,2,7}, Cor Liefink³,
14 Michiel van der Heijden^{3,8}, Matti Nykter⁵, Vincent van der Noort⁹, Joyce Sanders¹⁰, Ben Morris³, Guido
15 Jenster¹¹, Geert JLH van Leenders¹², Mark Pomerantz¹³, Matthew L. Freedman^{13,14}, Roderick L. Beijersbergen⁶,
16 Alfonso Urbanucci^{5,15}, Lodewyk Wessels^{2,3,16}, Eva Corey⁴, Wilbert Zwart^{1,2,17#}, Andries M. Bergman^{1,8#}

17

18 **1** Division of Oncogenomics, The Netherlands Cancer Institute, Amsterdam, the Netherlands

19 **2** Oncode Institute, the Netherlands

20 **3** Division of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands

21 **4** Department of Urology, University of Washington, Seattle, WA, USA

22 **5** Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays
23 Cancer Centre, Tampere, Finland

24 **6** present working address: Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije
25 Universiteit Amsterdam, Amsterdam, the Netherlands

26 **7** present working address: Department of Molecular Biology, Faculty of Science, Radboud Institute for
27 Molecular Life Sciences, Oncode Institute, Radboud University Nijmegen, 6525 GA Nijmegen, The Netherlands.

28 **8** Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

29 **9** Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

30 **10** Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands

31 **11** Department of Urology, Erasmus MC, Rotterdam, The Netherlands

32 **12** Department of Pathology, Erasmus MC Cancer Institute, University Medical Centre, Rotterdam, The
33 Netherlands.

34 **13** Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

35 **14** The Eli and Edythe L. Broad Institute, Cambridge, MA, USA

36 **15** Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway

37 **16** Department of EEMCS, Delft University of Technology, Delft, The Netherlands.

38 **17** Laboratory of Chemical Biology and Institute for Complex Molecular Systems, Department of Biomedical
39 Engineering, Eindhoven University of Technology, Eindhoven, The Netherlands.

40

41 *shared first authors

42 # corresponding authors: w.zwart@nki.nl, a.bergman@nki.nl

43 **Supplementary Clinical Methods**

44 *Baseline characteristics and response data*

45 In Supplementary Table 1, the baseline characteristics of all 64 included patients (whole
46 population) are summarized. Median age of the patients was 69 years and the majority of
47 patients had skeletal (75.0%) and/or lymph node (70.3%) metastases, while 34.4% had
48 visceral organ metastases. Virtually all patients (93.8%) had PSA progression, while
49 radiographic progression was established in 81.3% of patients prior to enzalutamide
50 treatment. Approximately one-third of patients (32.8%) received enzalutamide as a first line
51 mCRPC treatment, while all other patients previously received other treatments, including
52 docetaxel chemotherapy (62.5%) and the AR-signaling targeting agent abiraterone (23.4%).
53 Outcomes of treatment, after a median of 17 (IQR: 9-30) months follow-up, are summarized
54 in Supplementary Table 2. All patients in the trial were treated with enzalutamide (160 mg
55 once daily), except for one patient who was treated with abiraterone instead. The median
56 duration of treatment was 22.7 (IQR: 13-45) weeks and 46.9% of patients had a $\geq 50\%$
57 decrease of serum PSA from baseline. Complete or partial response was found in 18.8% of
58 patients and 17.2% of patients had radiographic stable disease after 12 weeks of treatment.
59 The primary endpoint of the trial, Time to PSA progression (TTPP) was 17.7 (IQR 12-35)
60 weeks, while median overall survival was 14.5 months.

61

62 Rate of PSA response in the current study (enzalutamide-treated in first, second and later
63 treatment lines) was lower than in the randomized controlled trial of first line enzalutamide
64 (PREVAIL trial) (78%)¹, but in line with the randomized controlled trial of second line
65 enzalutamide (AFFIRM trial) (54%)². The primary endpoint of the trial, Time to PSA
66 progression (TTPP) was 17.7 (IQR 12-35) weeks which falls within the expected range
67 considering 23.4% of patients in the current trial were previously treated with abiraterone and

68 consequently likely to have a lower likelihood of durable response due to cross-resistance³.
69 However, the composition of patients in the trial, based on the line of treatment, deferred from
70 the assumption that 60% percent of patients would have been treated with enzalutamide as
71 a third or higher line of mCRPC treatment. This means that the trial population had fewer
72 prior treatments than anticipated. The TTPP in the current trial was shorter than in the
73 AFFIRM trial (36 weeks)². Complete or partial response was found in 18.8% of patients and
74 17.2% of patients had radiographic stable disease after 12 weeks of treatment. Overall
75 survival was 14.5 months which was shorter than the 18.4 months, reported in the AFFIRM
76 study².

77

78 In conclusion, enzalutamide treatment resulted in a TTPP within the expected range. The
79 TTPP was shorter than in the registration studies PREVAIL and AFFIRM, which is explained
80 by the miscellaneous population with more pretreatments, most notably prior abiraterone.

81

82 *Trial procedure and patient outcomes*

83 Baseline studies included radiographic evaluation (CT scan of thorax and abdomen), physical
84 examination, ECOG performance score, blood cell counts and serum chemistry and a biopsy
85 from a metastatic site. Subsequently, patients were treated with enzalutamide at a starting
86 dose of 160 mg/day (4 tablets of 40 mg once daily). Dose adjustments to as low as 80 mg/day
87 were allowed. During the course of enzalutamide treatment, physical examination, ECOG
88 performance score, blood analysis, including PSA measurements, was performed every four
89 weeks at the outpatient clinic. A radiographic response was evaluated at 12 weeks by means
90 of a CT scan of thorax and abdomen (RECIST1.1). Patients with bone only metastases were
91 considered progressive when new metastases were detected. In these patients, a response
92 to treatment could not be evaluated. Enzalutamide treatment was continued until progression

93 or intolerance and selection of subsequent treatment. Frequency of visits to the outpatient
94 clinic and assessments beyond enzalutamide treatment were at the discretion of the
95 physician. Primary endpoint of the study is Time to PSA Progression (TTPP) defined as time
96 from inclusion into the trial until date of a confirmed second PSA rise (PCWG3). Secondary
97 recorded clinical outcomes are, rate of $\geq 50\%$ serum PSA decrease from baseline,
98 radiographic response (RECIST 1.1 criteria) and overall survival (OS) defined as time from
99 inclusion into the trial until death.

100

101 *Trial statistical analysis*

102 For biomarker discovery purposes, we aimed to construct a cohort of enzalutamide treated
103 patients at various lines of mCRPC treatment in a Phase 2 clinical trial, which is
104 representative for the general population. The first line enzalutamide PREVAIL study¹
105 showed an 11.2 month (48.7 weeks) time to PSA progression (TTPP), while the second line
106 enzalutamide AFFIRM study² showed an 8.3 month (36.1 weeks) TTPP. A retrospective
107 study into enzalutamide treated patients in fourth or fifth line, suggested a TTPP of 3.6 months
108 (15.7 weeks)⁴. We assumed to enroll 20% of patients treated with enzalutamide as a first line
109 treatment, 20% as a second and 60% of patients in a higher line of treatment. Consequently,
110 we expect a TTPP in this miscellaneous population of 22 weeks. Inclusion of 60 patients will
111 allow the detection of this median TTPP with 95% confidence intervals of 16.4-33.6 weeks.
112 This expected range is sufficiently narrow, that when the true TTPP falls within these limits,
113 it suggests that results of the trial are representative and can be interpreted clinically. All time-
114 to-event endpoints were estimated by the Kaplan-Meier method. Differences in normally
115 distributed baseline characteristics and study outcomes between the whole population and
116 the evaluable pre-treatment biopsy and post-treatment biopsy sub populations were
117 evaluated by a student t-test.

118

119 Supplemental Methods References

- 120 1 Beer, T. M. *et al.* Enzalutamide in metastatic prostate cancer before chemotherapy. *N Engl J*
121 *Med* **371**, 424-433 (2014). <https://doi.org:10.1056/NEJMoa1405095>
- 122 2 Scher, H. I. *et al.* Increased survival with enzalutamide in prostate cancer after chemotherapy.
123 *N Engl J Med* **367**, 1187-1197 (2012). <https://doi.org:10.1056/NEJMoa1207506>
- 124 3 Khalaf, D. J. *et al.* Optimal sequencing of enzalutamide and abiraterone acetate plus
125 prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised,
126 open-label, phase 2, crossover trial. *Lancet Oncol* **20**, 1730-1739 (2019).
127 [https://doi.org:10.1016/S1470-2045\(19\)30688-6](https://doi.org:10.1016/S1470-2045(19)30688-6)
- 128 4 Badrising, S. K. *et al.* Enzalutamide as a Fourth- or Fifth-Line Treatment Option for Metastatic
129 Castration-Resistant Prostate Cancer. *Oncology* **91**, 267-273 (2016).
130 <https://doi.org:10.1159/000448219>
131